# rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

> **NCT02702518** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Illinois at Chicago** · enrollment: 58 (actual)

## Conditions studied

- Ocular Graft vs Host Disease
- Dry Eye

## Interventions

- **DRUG:** rhDNase I
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT02702518
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2020-04-08
- **Final completion:** 2020-04-08
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** The DSMB committee recommended closing the trial because of the COVID-19 risk in this "at-risk" oGVHD population if they came for study visits.
- **Last updated:** 2021-09-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02702518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02702518, "rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02702518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*